Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Sponsor Directory

M.D. Anderson Cancer Center clinical trials

Sponsor pages show live ClinicalTrials.gov search results and objective aggregate stats only. They do not describe sponsor quality, reputation, or expected outcomes.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 4:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
3096
Shown on this page
12
Current sort
Recently updated
Sponsor scope
M.D. Anderson Cancer Center
Additional filters apply within this sponsor.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this sponsor

These controls apply only within M.D. Anderson Cancer Center. Default order is Recently updated. Add condition, therapy, location, or recruitment status to narrow this sponsor page further.

Reset sponsor filters
Clear filters
Showing 529–540 of 3,096 matching trials for sponsor M.D. Anderson Cancer Center.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Recruiting Phase 1 Interventional

A Phase1 Clinical Trial Evaluating Locoregional Delivery Of Engineered NK Cells Containing IL13Ra And EGFvIII Chimeric Antigen Receptor (CAR), IL-21 Secretion And Deleted TGF-BetaR2 And NR3C1 In Recurrent Glioblastoma

NCT07579208
View directory record Official record
Conditions
Phase 1, NK Cell, IL13Ra, EGFRvIII, Chimera Antigen Receptor (CAR), NR3C1, Recurrent Glioblastoma
Interventions
NK Cells
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 16, 2026, 4:05 PM EDT
Recruiting Phase 2 Interventional

Trial of AMB-05X for Patients With ctDNA(+) Colorectal Cancer After Curative-intent Treatment

NCT06617858
View directory record Official record
Conditions
Colorectal Cancer
Interventions
AMB-05X
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 16, 2026, 4:05 PM EDT
Active, not recruiting Phase 2 Interventional

Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery

NCT03007030
View directory record Official record
Conditions
CD30-Positive Neoplastic Cells Present, Malignant Mesothelioma
Interventions
Brentuximab Vedotin, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 16, 2026, 4:05 PM EDT
Recruiting Phase 2 Interventional

CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

NCT04493164
View directory record Official record
Conditions
Acute Myeloid Leukemia With Gene Mutations, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions
Ivosidenib, Liposome-encapsulated Daunorubicin-Cytarabine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 16, 2026, 4:05 PM EDT
Active, not recruiting Phase 1 Interventional

Tegavivint for the Treatment of Relapsed or Refractory Leukemia

NCT04874480
View directory record Official record
Conditions
Recurrent Leukemia, Refractory Leukemia
Interventions
Decitabine, Tegavivint
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 16, 2026, 4:05 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Pilot Presurgical Trial of REGN5678 (Anti-PSMA x CD28) in Patients With High-risk, Localized Prostate Cancer Followed by Radical Prostatectomy

NCT06085664
View directory record Official record
Conditions
Prostate Cancer, Radical Prostatectomy
Interventions
REGN5678, Piflufolastat F18
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 16, 2026, 4:05 PM EDT
Suspended Phase 2 Interventional

Phase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine/Tipiracil and Bevacizumab for Patients Refractory to Standard of Care Treatment and With Microsatellite-stable Colorectal Cancer

NCT07011550
View directory record Official record
Conditions
Microsatellite-stable Colorectal Cancer, Standard of Care, Nivolumab, Bevacizumab
Interventions
Nivolumab, Bevacizumab, BMS-986340, Trifluridine + Tipiracil
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 16, 2026, 4:05 PM EDT
Not yet recruiting Not applicable Interventional

Prospective Randomized Study of TPS + CBT VS TPS Alone: Readmission, Opioid Use, and Chronic Pain

NCT07783672
View directory record Official record
Conditions
Pain
Interventions
Transitional Pain Service
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2031
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 16, 2026, 4:05 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Hyperpolarized 129-Xenon Imaging in Adult Hematopoietic Cell Transplant Recipients With Pulmonary Impairment

NCT05041140
View directory record Official record
Conditions
Pulmonary, Pneumonia, Hematopoietic System--Cancer
Interventions
29-XeMRI imaging
Device
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 16, 2026, 4:05 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

A Phase 1 Open-Label, Dose-Ranging Safety and Pharmacokinetics Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML)

NCT07053020
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML)
Interventions
Cytarabine, Oral Cladribine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 16, 2026, 4:05 PM EDT
Recruiting Phase 2 Interventional

Pilot Study of Ivonescimab in Advanced/Metastatic Cutaneous Angiosarcoma

NCT07655570
View directory record Official record
Conditions
Cutaneous Angiosarcoma
Interventions
Ivonescimab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 16, 2026, 4:05 PM EDT
Recruiting Phase 2 Interventional

A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)

NCT05035836
View directory record Official record
Conditions
Breast Cancer, HER2-positive
Interventions
Zanidatamab, Letrozole, Tamoxifen
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 16, 2026, 4:05 PM EDT

About this M.D. Anderson Cancer Center sponsor directory page

What this page lists
U.S. ClinicalTrials.gov public records where M.D. Anderson Cancer Center is the lead sponsor, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results
Use the filters above to scope by condition, intervention, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within M.D. Anderson Cancer Center trials.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, sponsor quality scoring, ranking of trials, or AI-generated medical summaries.

Related: all sponsor pages, browse by condition, browse by drug or therapy, browse by U.S. city, or open the full search for M.D. Anderson Cancer Center.